» Articles » PMID: 36765578

Cancer-Associated B Cells in Sarcoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Feb 11
PMID 36765578
Authors
Affiliations
Soon will be listed here.
Abstract

Despite being one of the first types of cancers studied that hinted at a major role of the immune system in pro- and anti-tumor biology, little is known about the immune microenvironment in sarcoma. Few types of sarcoma have shown major responses to immunotherapy, and its rarity and heterogeneity makes it challenging to study. With limited systemic treatment options, further understanding of the underlying mechanisms in sarcoma immunity may prove crucial in advancing sarcoma care. While great strides have been made in the field of immunotherapy over the last few decades, most of these efforts have focused on harnessing the T cell response, with little attention on the role B cells may play in the tumor microenvironment. A growing body of evidence suggests that B cells have both pro- and anti-tumoral effects in a large variety of cancers, and in the age of bioinformatics and multi-omic analysis, the complexity of the humoral response is just being appreciated. This review explores what is currently known about the role of B cells in sarcoma, including understanding the various B cell populations associated with sarcoma, the organization of intra-tumoral B cells in tertiary lymphoid structures, recent trials in immunotherapy in sarcoma, intra-tumoral immunoglobulin, the pro-tumor effects of B cells, and exciting future areas for research.

Citing Articles

The role of neutrophils in osteosarcoma: insights from laboratory to clinic.

Xia M, Han Y, Sun L, Li D, Zhu C, Li D Front Immunol. 2024; 15:1490712.

PMID: 39582869 PMC: 11582048. DOI: 10.3389/fimmu.2024.1490712.


Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma.

Lacinski R, Dziadowicz S, Roth C, Ma L, Melemai V, Fitzpatrick B Front Oncol. 2024; 14:1417459.

PMID: 39493449 PMC: 11527601. DOI: 10.3389/fonc.2024.1417459.


Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.

Nirala B, Yamamichi T, Petrescu D, Shafin T, Yustein J Cancers (Basel). 2023; 15(20).

PMID: 37894474 PMC: 10605493. DOI: 10.3390/cancers15205108.


IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.

Klingbeil K, Tang J, Graham D, Lofftus S, Jaiswal A, Lin T Cancers (Basel). 2023; 15(18).

PMID: 37760460 PMC: 10526143. DOI: 10.3390/cancers15184489.


Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?.

Wang J, Ge H, Tian Z Onco Targets Ther. 2023; 16:385-397.

PMID: 37313391 PMC: 10258041. DOI: 10.2147/OTT.S410693.

References
1.
Jenks S, Cashman K, Woodruff M, Lee F, Sanz I . Extrafollicular responses in humans and SLE. Immunol Rev. 2019; 288(1):136-148. PMC: 6422038. DOI: 10.1111/imr.12741. View

2.
Cooper M, Peterson R, GOOD R . DELINEATION OF THE THYMIC AND BURSAL LYMPHOID SYSTEMS IN THE CHICKEN. Nature. 1965; 205:143-6. DOI: 10.1038/205143a0. View

3.
Hemminger J, Toland A, Scharschmidt T, Mayerson J, Guttridge D, Iwenofu O . Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol. 2014; 27(9):1238-45. PMC: 4287229. DOI: 10.1038/modpathol.2013.244. View

4.
Yagawa Y, Robertson-Tessi M, Zhou S, Anderson A, Mule J, Mailloux A . Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy. Sci Rep. 2017; 7(1):15996. PMC: 5700067. DOI: 10.1038/s41598-017-15924-2. View

5.
Shurell E, Vergara-Lluri M, Li Y, Crompton J, Singh A, Bernthal N . Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget. 2016; 7(45):72860-72867. PMC: 5341949. DOI: 10.18632/oncotarget.12096. View